Market Cap 7.25B
Revenue (ttm) 130.13M
Net Income (ttm) -260.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -200.26%
Debt to Equity Ratio 0.00
Volume 356,000
Avg Vol 582,778
Day's Range N/A - N/A
Shares Out 66.42M
Stochastic %K 75%
Beta 2.12
Analysts Strong Sell
Price Target $118.00

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid r...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 264 4280
Fax: 857 264 4299
Address:
222 Berkeley Street, 12th Floor, Boston, United States
profitraider
profitraider Oct. 23 at 11:54 PM
$RYTM Listen, I told you long ago that this was going to happen, but you didn’t want to listen… and, all I got was being laughed at!
2 · Reply
biolover
biolover Oct. 23 at 1:11 AM
$VKTX $NVO Sema price will not be $150 / month. It is hard to imagine by what mechanism the admin will enforce that. And this indirectly means $LLY demise , which committed $50 B for manufacturing. Most compounders sell for $200. $RYTM $SLNO sell wt loss drugs for BWS in the range of $500 k to $1 M annually ( outrageous ) Regardless what Trump stated ( his $150 is like the 1000% drop ) both Lilly and novo can rely on cash pay and not even care about Medicare. Novo clear # 1 problem is coming up with something competitive with tirzepatide more than anything else. Look at the growth rate of both drugs. This is an informed customers segment
2 · Reply
TeeMan123
TeeMan123 Oct. 22 at 4:42 PM
$RYTM never trust mgmt blindly… but when it comes to David Meeker you have to trust the guy until he gives you a reason not too… he sees something in pws, he has long history of never just starting a trial on a whim.. trust the process
0 · Reply
abcdzepeda
abcdzepeda Oct. 21 at 11:14 PM
$RYTM RYTM is reporting earnings on November 4, hopefully they use this day to give us the data on PWS. 
2 · Reply
TeeMan123
TeeMan123 Oct. 21 at 4:45 PM
$RYTM I have no idea why we are having a bear raid, safe to assume it has to do with pws positioning… but in moments like this it feels great to David Meeker at the helm who executes and doesn’t mess around.
1 · Reply
S_Franconi
S_Franconi Oct. 21 at 3:51 PM
0 · Reply
judgeyoung2
judgeyoung2 Oct. 20 at 9:06 PM
$RYTM Disclose preliminary results from the Company’s setmelanotide Phase 2 trial in Prader-Willi syndrome in the second half of 2025;
0 · Reply
abcdzepeda
abcdzepeda Oct. 20 at 5:23 PM
0 · Reply
TeeMan123
TeeMan123 Oct. 18 at 3:59 PM
$RYTM with strong pws data.. this company fetches $210 in a buyout
1 · Reply
TeeMan123
TeeMan123 Oct. 18 at 3:42 PM
$RYTM if they had enough data to make dramatic changes to the trial design (multi center/52 week trial); why didn’t they simply report out the data they promised the street?? Finalizing M&A discussions???
0 · Reply
Latest News on RYTM
Rhythm Pharmaceuticals, Inc. - Special Call

Sep 24, 2025, 5:07 PM EDT - 4 weeks ago

Rhythm Pharmaceuticals, Inc. - Special Call


Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 25, 2025, 11:21 AM EST - 8 months ago

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven


profitraider
profitraider Oct. 23 at 11:54 PM
$RYTM Listen, I told you long ago that this was going to happen, but you didn’t want to listen… and, all I got was being laughed at!
2 · Reply
biolover
biolover Oct. 23 at 1:11 AM
$VKTX $NVO Sema price will not be $150 / month. It is hard to imagine by what mechanism the admin will enforce that. And this indirectly means $LLY demise , which committed $50 B for manufacturing. Most compounders sell for $200. $RYTM $SLNO sell wt loss drugs for BWS in the range of $500 k to $1 M annually ( outrageous ) Regardless what Trump stated ( his $150 is like the 1000% drop ) both Lilly and novo can rely on cash pay and not even care about Medicare. Novo clear # 1 problem is coming up with something competitive with tirzepatide more than anything else. Look at the growth rate of both drugs. This is an informed customers segment
2 · Reply
TeeMan123
TeeMan123 Oct. 22 at 4:42 PM
$RYTM never trust mgmt blindly… but when it comes to David Meeker you have to trust the guy until he gives you a reason not too… he sees something in pws, he has long history of never just starting a trial on a whim.. trust the process
0 · Reply
abcdzepeda
abcdzepeda Oct. 21 at 11:14 PM
$RYTM RYTM is reporting earnings on November 4, hopefully they use this day to give us the data on PWS. 
2 · Reply
TeeMan123
TeeMan123 Oct. 21 at 4:45 PM
$RYTM I have no idea why we are having a bear raid, safe to assume it has to do with pws positioning… but in moments like this it feels great to David Meeker at the helm who executes and doesn’t mess around.
1 · Reply
S_Franconi
S_Franconi Oct. 21 at 3:51 PM
0 · Reply
judgeyoung2
judgeyoung2 Oct. 20 at 9:06 PM
$RYTM Disclose preliminary results from the Company’s setmelanotide Phase 2 trial in Prader-Willi syndrome in the second half of 2025;
0 · Reply
abcdzepeda
abcdzepeda Oct. 20 at 5:23 PM
0 · Reply
TeeMan123
TeeMan123 Oct. 18 at 3:59 PM
$RYTM with strong pws data.. this company fetches $210 in a buyout
1 · Reply
TeeMan123
TeeMan123 Oct. 18 at 3:42 PM
$RYTM if they had enough data to make dramatic changes to the trial design (multi center/52 week trial); why didn’t they simply report out the data they promised the street?? Finalizing M&A discussions???
0 · Reply
abcdzepeda
abcdzepeda Oct. 18 at 2:55 AM
1 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 5:21 PM
Goldman Sachs has updated their rating for Rhythm Pharmaceuticals ( $RYTM ) to Buy with a price target of 139.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 17 at 10:26 AM
WATCHLIST OCT 17 2025 $VHC VirnetX Holding Wins General Services Administration Multiple Award Schedule Contract; Contract Expands Federal Access To Secure Communications And Zero-Trust Cybersecurity Solutions $CTSH Cognizant Expands AI Services Portfolio With Enterprise Vibe Coding Blueprint To Drive Enterprise-Wide Transformation $GNL Global Net Lease Upgraded To Investment Grade By Fitch To BBB- From BB+, Backed By $3B Asset Dispositions (Including $1.8B Retail Sale) And August 2025 Revolving Credit Refinance $RYTM Morgan Stanley Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $129 $KZR Kezar Life Sciences Initiates Strategic Alternatives Review, Announces Workforce Restructuring And Rights Plan Extension After FDA Blocks Path Forward For Zetomipzomib In Autoimmune Hepatitis; Reports $90.2M Cash Balance
0 · Reply
abcdzepeda
abcdzepeda Oct. 16 at 8:04 PM
$RYTM we closed green on a sea of red day, I will take that! 
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 6:01 PM
Morgan Stanley has adjusted their stance on Rhythm Pharmaceuticals ( $RYTM ), setting the rating to Overweight with a target price of 122 → 129.
0 · Reply
Metrobilly
Metrobilly Oct. 16 at 3:30 PM
$RYTM Plus 277%. Like this stock!
0 · Reply
MaverikIT
MaverikIT Oct. 16 at 2:16 PM
@IsabellaDC @TheLongVol $PRAX - massive Holy $GRAL $VKTX getting into the $RYTM
0 · Reply
InvestorWisdom
InvestorWisdom Oct. 16 at 2:57 AM
$SPRO chart: Relative strength is increasing + MAs are aligned and curving up… the volume on this chart is distorted because of that one spike, but it’s slowly picking up the past 7 days. It just needs a volume spike to accelerate the trend… and it could happen soon with this attractive setup. This chart is calling traders to the playground Also, biotech stocks are heating up. $IBB & $XBI (biotech ETFs) just hit the highest price since 2022 this week…. And my other biotechs holdings like $RYTM are $INSM are strong This sector is also one of the biggest beneficiaries of AI progress …
0 · Reply
TeeMan123
TeeMan123 Oct. 16 at 2:06 AM
$RYTM EXTREMELY BULLISH IMO
0 · Reply
TeeMan123
TeeMan123 Oct. 16 at 1:53 AM
$RYTM holy smokes… the company updated the trial design for pws on clinical trials. org, adjusting the trial design to multi center and extending duration to 52 weeks, one would think you don’t make a trial bigger/longer if their isn’t an obvious signal being seen 🤔 !!!!!!!!!!!
1 · Reply
Doozio
Doozio Oct. 15 at 11:35 PM
🐒🍌🧠 $ZYME ♾️ is in $RYTM in its PRIM
0 · Reply
Metrobilly
Metrobilly Oct. 15 at 4:32 PM
$RYTM How do I post a picture of a rocket ship?
1 · Reply